ECONOMIC EVALUATION OF CHELATION REGIMENS FOR β--THALASSEMIA MAJOR: A SYSTEMATIC REVIEW

Main Article Content

Jialian Li *
(*) Corresponding Author:
Jialian Li | jialianlily@163.com

Abstract

Background:
Deferoxamine (DFO) or Deferiprone (DFP) or Deferasirox (DFX) monotherapy and DFO and DFP combination therapy were four commonly implemented now chelation regimens for the iron overloaded of β-thalassemia major. This systematic review aims to determine the cost-effectiveness of four chelation regimens and provide evidence for the rational use of chelation regimens for β-thalassemia major therapy in clinic.
Methods:
A systematic literature search in PubMed, EMBASE (Ovid), CENTRAL (Cochrane library), HTAD (Cochrane library), NHS EED (Cochrane library), CBM, CNKI, VIP, and Wanfang was conducted in April 2018. In addition, a manual search was performed. Two researchers, working independently, selected the papers, extracted the data and assessed the methodological quality of the included papers. Each included paper was evaluated using a checklist developed by Drummond et al.
Results:
The initial number of records was 968, and eight papers met the final eligibility criteria. All the included eight papers were cost-utility analyses. And the methodological quality of these papers was good. Nineteen studies were included in eight papers. Nine studies of DFX versus DFO had contradictory results. Out of the nineteen studies, three studies of DFX versus DFP established that using DFP was cost-effective. Three studies of DFP versus DFO established that using DFP was cost-effective. One study of DFP and DFO combination therapy versus DFO found that using DFO was cost-effective. One study of DFP and DFO combination therapy versus DFP found that using DFP was cost-effective. And there were two studies of DFP and DFO combination therapy versus DFX, but we cannot be sure which one of two chelation regimens was cost-effective.
Conclusion:
In brief, DFP is the best choice, followed by DFO or DFX, when an iron chelator is to be used alone for β-thalassemia major therapy. All studies that compared DFO and DFP combination therapy with DFO (or DFP or DFX) monotherapy established that the combination therapy with DFO and DFP was not cost-effective. However, due to the low number of related studies, more extensive, high-quality research is required for further analysis and confirmation of our findings. Moreover, the cost effectiveness is not an absolute issue when in different countries(regions) the results are opposite for other countries(regions). The specific region had a substantial influence on the economy of drugs.


Key words: β-thalassemia major, Deferoxamine, Deferiprone, Deferasirox, cost-effectiveness, systematic review


Downloads month by month

Downloads

Download data is not yet available.

Article Details

References

[1] Yang Y, Dai BT. The Iron Overload and Iron-Cheleting Therapying of β-thalassemia[J]. Journal of Pediatric Pharmacy, 2011, 17(3):58-61.
[2] Origa R. β-Thalassemia[J]. Genetics in Medicine, 2004, 1(6):14.
[3] Beijing AngelMom Charity Foundation, China Siyuan Foundation for Poverty Alleviation, China Philanthropy Research Institute of Beijing Normal University. Blue Paper of Thalassemia in China [M]. China Social Publishing House.2016.
[4] Angastiniotis M,Modell B.Global epidemiology of hemoglobin disorders[J].Ann N Y Acad Sci.1998.850:25l-259.
[5] Vichinsky EP.Changing patterns of thalassemia worldwide[J]. Ann NY Acad Sci,2005,1054:18-24.
[6] National Co-ordination Group of Haemoglobinopathy Research. A survey on hemoglobinopathy among 600,000 residents of 20 provinces, cities and autonomous regions of China[J]. Zhonghua Yi Xue Za Zhi, 1983, 63(6): 382-5.
[7] Hematology SGO, Association CM. Guidelines for the diagnosis and treatment of beta-thalassemia major[J]. Zhonghua Er Ke Za Zhi, 2010, 48(3):186-189.
[8] Rehm J , Chisholm D , Room R , et al. Disease control priorities in developing countries[M]. Oxford University Press , 2006.
[9] ee TA, von Riedemann S, Tricta F. Cost-utility of chelators in transfusion-dependent β-thalassemia major patients: a review of the pharmacoeconomic literature[J]. Expert Review of Pharmacoeconomics & Outcomes Research, 2014, 14(5):651-60.
[10] Neufeld E J. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions[J]. Blood, 2006, 107(9):3436-41.
[11] Neufeld E J. Update on iron chelators in thalassemia[J]. Hematology. American Society of Hematology. Education Program, 2010, 2010(6):451.
[12] Hematology SGO, Association CM. Guidelines for the diagnosis and treatment of beta-thalassemia major[J]. Zhonghua Er Ke Za Zhi, 2010, 48(3):186-189.
[13] Cappellini M D, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia[J]. Blood, 2006, 107(9):3455-62.
[14] Hematology Group, Society of Pediatrics, Chinese Medical Association. Guidelines for the diagnosis and treatment of severe beta-thalassemia [J].Chinese Journal of Pediatrics, 2010, 48(3):186-189.
[15] Kwiatkowski J L. Real-world use of iron chelators.[J]. Hematology, 2011, 2011(1):451-8.
[16] Pennell D J, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.[J]. Blood, 2006, 107(9):3738.
[17] Pennell D J, Udelson J E, Arai A E, et al. Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association[J]. Circulation, 2013, 128(13):E203-E203.
[18] Sheth, S., Weiss, M., Parisi, M., & Ni, Q. (2017). Clinical and Economic Burden of Transfusion-Dependent β-Thalassemia in Adult Patients in the United States. Blood, 130(Suppl 1), 2095. Accessed August 31, 2018.
[19] Esmaeilzadeh F, Azarkeivan A, Emamgholipour S, et al. Economic Burden of Thalassemia Major in Iran, 2015[J]. Journal of Research in Health Sciences, 2017, 16(3):111.
[20] Delea TE, Sofrygin O, Thomas SK, et al. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective[J]. PharmacoEconomics, 2007, 25(4):329-342.
[21] Luangasanatip N, Chaiyakunapruk N, Upakdee N, et al. Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study[J]. Clinical Drug Investigation, 2011, 31(7):493-505.
[22] Drummond M, O’Brien B, Stoddart G, Torrance G. Methods for economic evaluation of healthcare programmes. 4nd ed. Oxford: Oxford Medical Publications; 2015.
[23] Gc V, Wilson EC, Suhrcke M, et al. Are brief interventions to increase physical activity cost-effective? A systematic review[J]. British Journal of Sports Medicine, 2016, 50(7):408-417.
[24] Karnon J, Tolley K, Vieira J, et al. Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective.[J]. Clinical Drug Investigation, 2012, 32(12):805-15.
[25] Bentley A, Gillard S, Spino M, et al. Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective[J]. PharmacoEconomics, 2013, 31(12):1185-6.
[26] Ho W L, Chung K P, Yang S S, et al. A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan.[J]. Journal of the Formosan Medical Association, 2013, 112(4):221.
[27] Keshtkaran A, Javanbakht M, Salavati S, et al. Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients.[J]. Transfusion, 2013, 53(8):1722–1729.
[28] Walczak J, Sołtys E, Obrzut G, et al. PSY44. Cost-Utility Analysis of Deferasirox for the Treatment of Iron Overload Due to Frequent Blood Transfusions in the Children and Adolescents[J]. Value in Health, 2013, 16(7):A379.
[29] Pepe A, Rossi G, Bentley A, et al. Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in β-Thalassaemia Major Patients: An Italian Perspective.[J]. Clinical Drug Investigation, 2017:1-12.
[30] On September 28, 2018, China Foreign Exchange Exchange Trading Center was authorized to announce the announcement of the mid-price of RMB exchange rate.http://www.pbc.gov.cn/zhengcehuobisi/125207/125217/125925/3636555/index.html
[31] Kamon J, Tolley K, Oyee J, et al. Cost utility analysis of deferasirox (Exjade*) versus deferoxamine (Desferal) for patients requiring iron chelation therapy in the United Kingdom. Curr Med Res Opin 2008; 24 (6): 1609-21.
[32] the World Bank: http://data.worldbank.org.cn/indicator/NY.GDP.PCAP.CD